Consumer Insights
Uncover trends and behaviors shaping consumer choices today
Procurement Insights
Optimize your sourcing strategy with key market data
Industry Stats
Stay ahead with the latest trends and market analysis.
Brain Metastases represent the most common intracranial tumors in adults, occurring in approximately 10-40% of patients with advanced solid cancers and contributing substantially to cancer-related morbidity and mortality. The growing incidence, driven by improved cancer survival and enhanced diagnostic imaging, continues to expand the need for innovative therapies. Brain metastases pipeline analysis by Expert Market Research highlights a diverse portfolio of investigational candidates focused on targeted therapies, novel drug delivery platforms, and precision medicine approaches to improve intracranial disease management and patient outcomes.
Major companies involved in the brain metastases pipeline analysis include GT Medical Technologies, Inc., Allist Pharmaceuticals, Inc., and others.
Leading drugs currently in the pipeline include 186RNL, AO-252, and others.
The brain metastases pipeline is driven by advances in blood-brain barrier-penetrant therapeutics, targeted radiopharmaceuticals, intracranial drug delivery technologies, and biomarker-guided precision oncology. Increasing integration of stereotactic radiation with systemic therapies and the development of HER2- and EGFR-directed agents are accelerating innovation and expanding treatment opportunities for patients with metastatic brain tumors.
The Brain Metastases Pipeline Analysis Report by Expert Market Research gives comprehensive insights into brain metastases therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for brain metastases. The brain metastases report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The brain metastases pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with brain metastases treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to brain metastases.

Read more about this report - Request a Free Sample
The brain metastases pipeline continues to expand with increasing emphasis on therapies targeting intracranial malignancies and overcoming the challenges of the blood-brain barrier. In August 2025, the U.S. FDA granted accelerated approval to dordaviprone (Modeyso) for adult and pediatric patients with H3 K27M-mutant diffuse midline glioma following prior therapy. Although approved for diffuse midline glioma, this milestone reinforces confidence in neuro-oncology drug development and is expected to stimulate innovation in investigational therapies addressing brain metastases.
Brain Metastases are the most common intracranial tumors in adults, occurring in approximately 10-40% of patients with advanced solid malignancies and accounting for an estimated 200,000-400,000 new cases annually in the United States. Lung cancer, breast cancer, and melanoma remain the leading primary tumors associated with brain metastases. The incidence continues to increase due to improved systemic cancer survival and greater use of advanced neuroimaging, enabling earlier detection and intervention for metastatic brain disease.
This section of the report covers the analysis of brain metastases drug candidates based on several segmentations, including:
By Phase
The pipeline assessment report covers 50+ drug analyses based on phase:
By Drug Class
The brain metastases pipeline analysis report covers 50+ drug analyses based on drug classes:
By Route of Administration
The pipeline assessment report covers 50+ drug analyses based on the route of administration:
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II covers a major share of the total brain metastases clinical trials. Early Phase I (3.02%), Phase I (21.12%), Phase II (58.19%), Phase III (15.52%), reflecting the distribution of drug candidates across the different stages of clinical development.
The drug molecule categories covered under the brain metastases pipeline analysis include small molecules, monoclonal antibodies, and cell therapies. The brain metastases report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for brain metastases. In August 2024, the U.S. FDA approved vorasidenib (Voranigo) for adults and children aged 12 years and older with Grade 2 IDH1/IDH2-mutant astrocytoma or oligodendroglioma following surgery.
The EMR report for the brain metastases pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed brain metastases therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in brain metastases clinical trials:
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for brain metastases. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of brain metastases drug candidates.
SHR-A1811 is an antibody-drug conjugate (ADC) developed by Jiangsu Hengrui Pharmaceuticals Co., Ltd. It combines a HER2-targeting monoclonal antibody with a cytotoxic payload to selectively eliminate HER2-expressing tumor cells associated with brain metastases, while minimizing damage to healthy tissues. The ongoing clinical study is expected to be completed in 2028. Hengrui Pharmaceuticals is a leading global biopharmaceutical company with a strong oncology pipeline focused on innovative biologics, ADCs, and targeted therapies for solid tumors.
186RNL is a radiopharmaceutical developed by Plus Therapeutics, Inc. for patients with brain metastases. The investigational therapy delivers the beta-emitting radioisotope rhenium-186 directly into intracranial tumors through convection-enhanced delivery, enabling localized radiation while reducing systemic exposure. The clinical program is expected to be completed in 2027. Plus Therapeutics is a clinical-stage pharmaceutical company specializing in targeted radiotherapeutics for central nervous system cancers and other difficult-to-treat malignancies.
DSB2455 is an antibody-drug conjugate (ADC) being developed by Duality Biologics for the treatment of brain metastases. The therapy is designed to selectively bind tumor-associated targets and deliver a potent cytotoxic agent directly into cancer cells, improving antitumor activity while limiting systemic toxicity. The ongoing clinical study is expected to be completed in 2028. Duality Biologics is a biotechnology company dedicated to advancing next-generation ADC platforms for oncology indications with significant unmet medical needs.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
The Brain Metastases Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for brain metastases. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into brain metastases collaborations, regulatory environments, and potential growth opportunities.
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Drug Classes |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Strategic Solutions for Informed Decision-Making
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.